StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for LFVN yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-14 | $5.27 | $5.12 | -2.85% | 0.1M |
| 05-15 | $5.02 | $5.17 | +2.99% | 0.1M |
| 05-18 | $5.23 | $5.19 | -0.76% | 0.1M |
| 05-19 | $5.13 | $5.26 | +2.53% | 0.1M |
| 05-20 | $5.25 | $5.25 | +0.00% | 0.1M |
Earnings (▲ beat / ▼ miss) and ex-dividend dates plotted on the price line. Educational — proximity does not establish causation.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Q4 2025 2025-12-31 | Q3 2025 2025-09-30 | Annual 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $140.21M | $96.49M | $47.56M | $228.53M |
Operating Income | $4.43M | $2.76M | $2.27M | $12.20M |
Net Income | $3.79M | $276.00K | $2.15M | $9.80M |
EPS (Diluted) | $0.30 | $0.19 | $0.17 | $0.75 |
Total Assets | $62.13M | $61.17M | $61.58M | $71.96M |
Total Liabilities | $28.79M | $28.18M | $28.42M | $37.32M |
Cash & Equivalents | $12.48M | $10.18M | $13.09M | $20.20M |
Free Cash Flow OCF − CapEx | $2.94M | $-1.04M | $-2.74M | $10.51M |
Shares Outstanding | 12.61M | 12.79M | 12.69M | 12.43M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.